These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2232168)

  • 1. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
    Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
    Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
    Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
    Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
    Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery].
    Sakurai Y; Kodaira S; Teramoto T; Sugano K; Abe O; Ohtake H; Iri H
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3205-12. PubMed ID: 2782914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
    Anzai K; Kurihara M; Izumi T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
    Suzuki S; Nihei M; Nomizu T; Watanabe T; Kimijima I; Tsuchiya A; Abe R
    Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):1019-26. PubMed ID: 2202768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
    Iemura K; Moriya Y
    Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
    Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
    Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of the NCC-ST-439 EIA kit using serum from patients with various types of cancer and benign disease (2)].
    Ohkura H; Hattori N; Miyazaki I; Sawabu N; Tobe R; Kawai K; Abe O; Ishii M; Kawai T; Kamano T
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1907-12. PubMed ID: 2439021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
    Nekulová M; Simícková M; Pecen L; Eben K; Vermousek I; Stratil P; Cernoch M; Lang B
    Neoplasma; 1994; 41(2):113-8. PubMed ID: 8208314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
    Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor marker: practical usage of tumor marker for recurrent breast cancer--our experience].
    Yoshimoto M
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2277-83. PubMed ID: 2241194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
    Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
    Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.